EDTUTC-4 New YorkLog in Sign up

REGN
Regeneron Pharmaceuticals Inc
stockNASDAQ

Market OpenOct 29, 2026 10:35:18 AM EDT

818.55USD+0.650%(+5.28)139,550

Pre-marketOct 29, 2026 9:25:30 AM EDT

827.20USD+1.713%(+13.93)

817.61Bid819.55Ask1.94Spread

REGN News

Day breaks

01:06 PM EDTSandoz falls as headwinds in Germany prompt cautious outlook ·

Seeking Alpha

12:43 PM EDTHas Regeneron Stock Become A Different Bet? ·

Trefis

11:43 AM EDTKiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst ·

Seeking Alpha

05:54 AM EDTRegeneron agrees to $270m extension to supply Ebola medicine in US ·

Pharmaceutical Technology

07:00 AM EDTRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness ·

GlobeNewswire Inc.

08:07 AM EDTEarnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more ·

Seeking Alpha

05:15 AM EDTLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) ·

GlobeNewswire Inc.

05:18 PM EDTAre You Overpaying For Regeneron Stock Versus Its Rivals? ·

Trefis

10:57 AM EDTIBB, REGN, NTRA, ARGX: Large Outflows Detected at ETF ·

BNK Invest

01:15 PM EDTHow Much Upside Is Left In Regeneron Stock? ·

Trefis

11:58 AM EDTRegeneron-backed Parabilis rises ahead of trial data for lead asset ·

Seeking Alpha

10:44 AM EDTForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ·

The Motley Fool

10:24 AM EDTForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ·

The Motley Fool

08:38 AM EDTEyePoint plunges after late-stage trial setback for lead drug against Eylea ·

Seeking Alpha

03:44 PM EDTForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ·

The Motley Fool

03:24 PM EDTForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ·

The Motley Fool

07:00 AM EDTLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types ·

GlobeNewswire Inc.

05:45 PM EDTWhat Could Send Regeneron Stock Higher? ·

Trefis

05:42 PM EDTRegeneron a new Buy at UBS as Street undervalues Dupixent's future ·

Seeking Alpha

06:00 AM EDTRegeneron reports 84-week Phase III data for Pasatru in adult FOP ·

Clinical Trials Arena